(CercleFinance.com) – Sanofi announces the presentation of positive results from a phase III trial evaluating the experimental use of its Dupixent in chronic obstructive pulmonary disease (COPD), at the international congress of the American Thoracic Society.
According to these results, published simultaneously in the NEJM, Dupixent is the first and only investigational biologic drug to achieve a significant 30% reduction in moderate to severe acute exacerbations compared to placebo.
It also significantly improved respiratory function at weeks 12 and 52, with numerical improvements by week two, and quality of life and respiratory symptoms, with numerical improvements by week four.
‘COPD is the third leading cause of death in the world and no new drug for the treatment of this disease has been approved for more than ten years’, underlines the French health giant.